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OBJECTIVES: Intravenous immunoglobulin (IGIV) made from
chromatography-caprylate methods (IGIV-C, 10%) was associ-
ated with a reduction in validated infections (pneumonia, sinusi-
tis and acute exacerbation of chronic sinusitis) when compared
to IGIV made from solvent-detergent methods (IGIV-SD, 10%)
in patients with primary immunodeﬁciency disease. Our objec-
tive was to determine the cost-effectiveness of IGIV-C.
METHODS: We performed a retrospective economic analysis of
a double-blind, randomized, clinical trial. Participants were ran-
domly assigned to IGIV-C (n = 87) or IGIV-SD (n = 85) and mon-
itored for the development of validated infections over the course
of 9 months. Consumed resources were enumerated including
cost of physician and emergency room visits, medications (pre-
scription and over-the-counter), work productivity losses and
hospitalizations. Resource data was obtained from case report
forms, patient diaries and the trial medication database. Unit
costs were obtained from national costing sources (Thomson’s
Redbook, Health Care Utilization Project database), etc. Pricing
of both IGIV products was the same therefore IGIV acquisition
costs were not included in the analyses. We used a societal per-
spective with indirect costs, measured in 2003 U.S. dollars.
RESULTS: In a multivariate analysis, mean per participant costs
were signiﬁcantly lower between those receiving IGIV-C com-
pared to IGIV-SD for prescription medications (-$302, 95% CI:
-$598, -$6), hospitalization (-$1454, 95% CI: -$1828, -
$1080) and total costs (-$1304, 95% CI: -$1867, -$742). Par-
ticipant costs associated with lost work productivity and
physician visits were similar for both groups (p > 0.10). In sen-
sitivity analyses, using 80% of average wholesale price for
costing prescription medications instead of 95%, the mean per
participant costs remained statistically lower for the IGIV-C
group. CONCLUSIONS: IGIV-C is cost-saving and provides
incremental health beneﬁts therefore it is a dominant strategy
compared to IGIV-SD. Differences in the process of
immunoglobulin manufacturing can lead to meaningful clinical
and economic outcome differences in the care.
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AN ECONOMIC AND CLINICAL ASSESSMENT OF FIRST-LINE
MONOTHERAPY IN THE TREATMENT OF COMMUNITY-
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OBJECTIVE: The objective of this study was to evaluate the
resource consumption and outcomes associated with ﬁrst-line
monotherapy for community-acquired pneumonia (CAP), focus-
ing speciﬁcally on the use of erythromycin, azithromycin, clar-
ithromycin, and levoﬂoxacin. METHODS: A retrospective
database analysis was conducted of patients diagnosed with
pneumonia from managed care organizations from January 1995
to April 2002. Linear and logistic regression models were used
to examine associations with treatment success rates and direct
medical costs between antibiotic treatments after controlling for
patient demographics and pneumonia risk factors. RESULTS:
Overall, treatment success rates were high (95.8%), the use of
second antibiotics was uncommon (2.3%), and hospitalizations
were infrequent (2.0%) among the 1952 patients studied. After
controlling for patient characteristics and risk factors, statisti-
cally lower total costs were associated with erythromycin
(92.7% lower), azithromycin (48.7% lower), and clarithromycin
(21.3% lower) relative to levoﬂoxacin, with no difference in
treatment success between groups. Post-hoc analyses assessing
subsets as 1) >50 years of age; 2) presentation of a comorbid
disease state; or 3) a chronic disease score (CDS) above 
the sample’s mean indicated that both erythromycin and
azithromycin were associated with statistically lower total costs
than levoﬂoxacin, while clarithromycin was not signiﬁcantly dif-
ferent. When limiting the assessment to only newer agents,
azithromycin (49.2% lower) and clarithromycin (21.7% lower)
were associated with lower total costs relative to levoﬂoxacin.
Additionally, in subjects with a CDS above the sample’s mean,
only azithromycin was associated with lower total costs (49.2%
lower) relative to levoﬂoxacin, with no differences observed con-
cerning treatment success. CONCLUSIONS: This real-world
analysis of managed care patients found that erythromycin,
azithromycin, and clarithromycin were associated with signiﬁ-
cantly lower total costs than levoﬂoxacin, without differences in
treatment success rates. Following stratiﬁcation based upon
various subset criteria, erythromycin and azithromycin were
observed to have signiﬁcantly lower total costs than levoﬂoxacin.
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OBJECTIVES: International studies have reported the overall
cost per patient associated with severe sepsis. However, there is
a lack of understanding about how the treatment cost and
resource utilization varies with failure of one or more organs.
This study was conducted to: 1) identify cost element ﬂow and
frequency of resource use to estimate aggregated cost for typical
ICU medical and surgical severe sepsis patients with various
organ dysfunctions, and 2) determine the prevalence of type of
organ failures and cost associated with the management in severe
sepsis patients with failure in two organs. METHODS: Retro-
spective review of the GSH administrative database from 1999
to 2002 of ICU severe sepsis patients (n = 889). Sepsis and organ
failure classiﬁcation was based on reported ICD-9-CM codes.
Resource utilization and cost data, through day 28, were
obtained from both ICU and non-ICU cost centers. RESULTS:
A matrix of the frequency of resource utilization and average
cost per resource associated with the severe sepsis treatment 
was generated. Resource categories included: room & board,
nursing, medications, operating room, laboratories, diagnostics,
physical therapy, and organ related treatment. The mean LOS
was 16.6 ± 15 days for all severe sepsis patients. Survivors had
an average 6 days greater LOS than non-survivors. The mean
total cost per severe sepsis patient abstracted was $29,390 ±
$24,673 ($1,594/day) for survivors, $27,837 ± $29,445
($2,268/day) for non-survivors, and $27,548 ± $22,824
($1,620/day) for sepsis patients with 2 acute organ failures.
Highest prevalence among patients with two organ dysfunctions
was Respiratory + (Cardiovascular or Renal) organ failures.
Average hospital mortality of severe sepsis patient was 30.2%.
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CONCLUSIONS: Retrospective database analysis has yielded a
previously unavailable resource allocation and cost structure that
illuminates our understanding of severe sepsis management 
economics.
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OBJECTIVE: Although treatment failure can substantially
increase medical-care costs, data on the economic impact of
treatment failure in acute bacterial maxillary sinusitis (ABMS)
are lacking. The absence of these data undermines efforts to
incorporate pharmacoeconomic criteria in clinical decision-
making (beyond simplistic comparisons of the acquisition costs
of competing antibiotics). We conducted this study to document
the cost of treatment failure in ABMS. METHODS: Data were
obtained from a prospective, randomized, double-blind, equiva-
lency study in which adults with radiographic evidence of ABMS
were randomized to treatment with telithromycin 800mg once
a day for 5 days followed by placebo for 5 days (n = 159) or
moxiﬂoxacin 400mg once a day for ten days (n = 163). Patients
were asked to record in a study diary all nonprotocol sinusitis-
related health-care utilization over a 30-day follow-up period,
including outpatient visits, tests and procedures, prescription
medications, and over-the-counter remedies. Unit costs were
assigned to all measures of health-care utilization using nation-
ally representative published sources. All utilization and cost
measures were analyzed irrespective of treatment assignment and
compared between patients who were treatment “successes”
versus “failures”, as assessed for the primary efﬁcacy endpoint.
RESULTS: A total of 253 subjects were declared treatment suc-
cesses and 47 treatment failures. Treatment failures incurred
sinusitis-related medical-care costs that were nearly sixfold
higher than treatment successes ($126.11 vs $21.98; p < 0.001),
reﬂecting higher mean utilization of unscheduled outpatient ser-
vices (0.40 vs 0.10 visits; p = 0.009), tests and procedures (0.32
vs 0.08; p = 0.002), and nonstudy prescription medications (1.23
vs 0.39; p < 0.001). Use of over-the-counter drugs did not differ
signiﬁcantly (0.68 vs. 0.54 units purchased; p = 0.763). CON-
CLUSIONS: The cost of treatment failure in ABMS appears to
be substantial. Clinical decision-making regarding choice of
antibiotic therapy in ABMS should involve consideration of how
treatment failure might increase overall costs of sinusitis-related
care.
PIN16
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OBJECTIVE: This study evaluates the cost-effectiveness of four
antimicrobial regimens (e.g., levoﬂoxacin monotherapy, ceftri-
axone monotherapy, ceftriaxone plus a macrolide, and ceftriax-
one plus levoﬂoxacin) for the treatment of patients admitted to
the medical ﬂoor with class IV or V community-acquired pneu-
monia (CAP). METHODS: All adult patients with a principal
discharge diagnosis of pneumonia, admitted to Baptist-Health
System from November 1, 1999 to April 30, 2000 were evalu-
ated. Medical ﬂoor patients who met criteria for Pneumonia
Severity Index (PSI) risk class IV or V were included in this analy-
sis. Total hospital charges were converted to costs using the 
hospital cost-to-charge ratio. Wilcoxon Rank Sum was used to
evaluate associations between antimicrobials received (indepen-
dent variable) and total hospital cost (dependent variable). Cost-
effectiveness ratios were determined by dividing the total
hospital cost by the percent survival. RESULTS: A total of 649
patients were managed on the medical ﬂoor with 415 (64%)
meeting the criteria for PSI risk class IV (N = 274) or V (N =
141) CAP. Costs (median, 25th and 75th quartile) were as
follows: total hospital cost ($4087 [$2590–$6554]), pharmacy
costs ($606 [$366–$1092]), and antibiotic costs ($112
[$66–$184]). Total hospital costs were lowest for levoﬂoxacin
monotherapy (N = 151, $3506 [$2231–$5870]), followed by 
ceftriaxone monotherapy (N = 61, $3758 [$2741–$6071]), 
ceftriaxone plus a macrolide (N = 61, $4163 [$3100–$5726]),
and ceftriaxone plus levoﬂoxacin (N = 38, $4830
[$2934–$7393]) (P = 0.0921). Survival was the highest for
patients who received ceftriaxone plus a macrolide (98%), fol-
lowed by ceftriaxone plus levoﬂoxacin (95%), levoﬂoxacin
monotherapy (94%), and ceftriaxone monotherapy (87%) 
(P = 0.0734). The most favorable cost-effectiveness ratio was
observed for patients who received levoﬂoxacin monotherapy
($3730 per expected cure), followed by ceftriaxone plus a
macrolide ($4248), ceftriaxone monotherapy ($4370), and cef-
triaxone plus levoﬂoxacin ($5367). CONCLUSION: Among
patients admitted to the medical ﬂoor for class IV or V CAP, lev-
oﬂoxacin monotherapy is the most cost-effective antimicrobial
regimen.
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OBJECTIVES: To present pharmacoeconomic evidence support-
ing the relative cost-effectiveness of two pegylated interferon
therapies, compared with the standard interferon and ribavirin
therapy, for hepatitis C treatment. METHODS: Evidence-based
decision analysis based on genotypes, treatment dose and dura-
tion, comparing the pharmacoeconomic beneﬁts of PEGASYS +
COPEGUS (peginterferon alfa-2a + ribavirin) versus REBE-
TRON (interferon alfa-2b + ribavirin) and PEG-Intron +
REBETOL (peginterferon alfa-2a + ribavirin) versus REBE-
TRON. Cost effectiveness is calculated in terms of the cost per
sustained virological response (SVR); timeframe includes the
course of therapy and treatment-free follow-up of 24-weeks. The
model adopts a managed care perspective and includes only
direct costs. Each therapy efﬁcacy rates, total costs, costs asso-
ciated with diagnosis, medical treatment, drug acquisition and
adverse events are calculated for base-case scenario and sensi-
tivity analyses. RESULTS: Drugs accounted for the largest
portion of total costs, followed by adverse events, diagnostic pro-
cedures and medical treatment. The total costs associated with
PEG-Intron+REBETOL ($29,510) compared with REBETRON
($25,864) imply an incremental cost-effectiveness ratio (ICER)
for PEG-Intron+REBETOL versus REBETRON of $60,767.
PEGASYS + COPEGUS provide an increased probability of
treatment success at a lower cost than REBETRON. Compared
with REBETRON, the combination of PEGASYS + COPEGUS
is deemed a dominant strategy. The results of the sensitivity
